Even though there is still a need for major improvements, it is beyond question that CD19-CAR-T cells and tisagenlecleucel especially are novel therapeutics that have contributed significantly to better outcome and prolonged survival in r/r pediatric BCP-ALL patients. Here, CD19 is linked to acute lymphoblastic leukemia.